Alzheimer’s disease

Neuroprotective Effects of Mushroom Biomass Digestive Fractions and Gut Microbiota Metabolites in Microglial and Caenorhabditis elegans Models of Neurodegeneration

mycolabadmin

This study tested whether common and medicinal mushrooms could protect against Alzheimer’s disease by reducing harmful reactive oxygen species in brain cells. Researchers tested three mushroom types using digestive simulation to see what the body could absorb, plus key compounds made by gut bacteria. The mushroom extracts and certain bacterial metabolites successfully reduced cellular damage markers and improved behavior in disease-model worms, suggesting mushroom-rich diets may help prevent neurodegeneration.

Sporoderm-removed ganoderma lucidum spore powder (S-GLSP) alleviates neuroinflammation injury by regulating microglial polarization through inhibition of NLRP3 inflammasome activation

mycolabadmin

Researchers found that sporoderm-removed Ganoderma lucidum spore powder (S-GLSP) protects against Alzheimer’s disease by reducing brain inflammation. The supplement works by shifting immune cells in the brain called microglia from a harmful pro-inflammatory state to a protective anti-inflammatory state. This is accomplished by blocking the NLRP3 inflammasome, a key trigger of brain inflammation. In animal and cell studies, S-GLSP improved memory, reduced neuronal damage, and decreased harmful tau protein accumulation.

Assessment of Lab4P Probiotic Effects on Cognition in 3xTg-AD Alzheimer’s Disease Model Mice and the SH-SY5Y Neuronal Cell Line

mycolabadmin

Researchers tested a probiotic supplement called Lab4P on mice genetically engineered to develop Alzheimer’s-like symptoms and on human brain cells exposed to damaging proteins. The supplement successfully improved memory and cognitive function in the mice while protecting brain cells from damage, with stronger benefits when the mice were also on a high-fat diet. These findings suggest that probiotics might help prevent or slow cognitive decline related to Alzheimer’s disease.

Long term worsening of amyloid pathology, cerebral function, and cognition after a single inoculation of beta-amyloid seeds with Osaka mutation

mycolabadmin

Researchers found that a single exposure to mutated amyloid-beta proteins (Aβ Osaka) in the brains of genetically modified mice caused lasting damage over four months. The mutated proteins triggered more severe memory loss, brain connectivity problems, and synapse damage compared to normal amyloid-beta. This suggests that even one encounter with mutated amyloid proteins can set off a chain reaction of disease progression that persists long after initial exposure.

Microbial links to Alzheimer’s disease

mycolabadmin

This review examines whether germs like bacteria, fungi, and viruses might play a role in causing Alzheimer’s disease. Scientists have found that certain bacteria from the mouth and gut, fungal infections, and cold sores (herpes viruses) appear more frequently in Alzheimer’s patients and may trigger the brain changes that damage memory and thinking. While the evidence is promising, researchers still need to determine whether these infections actually cause Alzheimer’s or simply make it worse once it develops.

Synaptic degeneration in the prefrontal cortex of a rat AD model revealed by volume electron microscopy

mycolabadmin

Researchers used advanced microscopy techniques to examine brain tissue from rats with Alzheimer’s disease and compared it to healthy rats. They found that Alzheimer’s disease causes damage to connections between brain cells (synapses) in a brain region important for thinking and memory. Specifically, the connections were weaker and smaller, and many new spine-like structures formed but didn’t properly connect to other cells, suggesting the brain may be trying unsuccessfully to compensate for the disease.

Neuroprotective properties of anti-apoptotic BCL-2 proteins in 5xFAD mouse model of Alzheimer’s disease

mycolabadmin

Scientists studied how Bcl-2 proteins might protect the brain from Alzheimer’s disease by controlling calcium levels in nerve cells. They injected modified Bcl-2 proteins into the brains of mice engineered to develop Alzheimer’s symptoms and found that these proteins helped preserve the connections between nerve cells and reduced harmful amyloid plaque buildup. A special version of Bcl-2 that worked primarily on one type of calcium channel was surprisingly most effective at reducing amyloid plaques, suggesting this specific mechanism could be important for treating Alzheimer’s disease.

β-secretase inhibition prevents structural spine plasticity deficits in AppNL-G-F mice

mycolabadmin

Researchers tested whether a drug that blocks BACE1 (an enzyme involved in Alzheimer’s disease) could protect nerve cell connections in a mouse model of Alzheimer’s disease. They found that at high doses, the drug significantly improved the formation of new dendritic spines (connection points between neurons) and restored synaptic activity to near-normal levels. These findings suggest that using BACE1 inhibitors early in Alzheimer’s disease development, before widespread neuronal damage occurs, might help prevent cognitive decline.

New Positive TRPC6 Modulator Penetrates Blood–Brain Barrier, Eliminates Synaptic Deficiency and Restores Memory Deficit in 5xFAD Mice

mycolabadmin

Researchers developed a new drug candidate called C20 that activates TRPC6 proteins in the brain. In studies with Alzheimer’s disease mouse models, C20 protected nerve connections from damage, restored memory function, and successfully crossed the blood-brain barrier. The compound shows promise as a potential treatment for Alzheimer’s disease by strengthening the connections between brain cells that are damaged in the disease.

Evaluating the antioxidant, anti-inflammatory, and neuroprotective potential of fruiting body and mycelium extracts from edible yellow morel (Morchella esculenta L. Pers.)

mycolabadmin

This study examined morel mushrooms from Pakistan to see if they could help treat Alzheimer’s disease and related brain conditions. Researchers tested both the fruiting bodies and the root-like mycelia of Morchella esculenta mushrooms for their ability to fight oxidative stress, reduce inflammation, and inhibit an enzyme that breaks down acetylcholine, a brain chemical important for memory. The results showed that morel extracts, especially from fruiting bodies collected in certain regions, worked as well as or better than conventional medications, suggesting these common edible mushrooms could be developed into treatments for neurodegenerative diseases.

Research Topic: Alzheimer's disease